Ogaki Keitaro, Fujita Hiroaki, Nozawa Narihiro, Shiina Tomohiko, Sakuramoto Hirotaka, Suzuki Keisuke
Department of Neurology, Dokkyo Medical University, Tochigi, Japan.
Front Neurol. 2023 Mar 9;14:1097251. doi: 10.3389/fneur.2023.1097251. eCollection 2023.
Sleep disturbances and excessive daytime sleepiness (EDS) are common non-motor symptoms in patients with Parkinson's disease (PD). The purpose of this study was to identify the contributors to sleep disturbances, including insomnia, restless legs syndrome, rapid eye movement sleep behavior disorder (RBD), sleep-disordered breathing, nocturnal akinesia and EDS, in patients with PD.
We conducted a cross-sectional study including 128 consecutive Japanese patients with PD. Sleep disturbances and EDS were defined as a PD Sleep Scale-2 (PDSS-2) total score ≥15 and an Epworth Sleepiness Scale (ESS) score >10, respectively. The patients were divided into four groups according to the presence or absence of sleep disturbances and EDS. We evaluated the disease severity, motor symptoms, cognition, olfactory test, the Scales for Outcomes in PD-Autonomic dysfunction (SCOPA-AUT), the Beck Depression Inventory-II (BDI-II), and the RBD Screening Questionnaire Japanese version (RBDSQ-J).
Of 128 patients, 64 had neither EDS nor sleep disturbances, 29 had sleep disturbances without EDS, 14 had EDS without sleep disturbances, and 21 had both EDS and sleep disturbances. Patients with sleep disturbances had higher BDI-II scores than those without sleep disturbances. Probable RBD was more frequent in patients with both sleep disturbances and EDS than in those with neither EDS nor sleep disturbances. The SCOPA-AUT score was lower in patients with neither EDS nor sleep disturbances than in patients in the other three groups. Using multivariable logistic regression analysis with neither sleep disturbances nor EDS as a reference group, that the SCOPA-AUT score was an independent contributor to sleep disturbances (adjusted OR, 1.192; 95% CI, 1.065-1.333; = 0.002) or EDS (OR, 1.245; 95% CI, 1.087-1.424; = 0.001) and that the BDI-II (OR, 1.121; 95% CI, 1.021-1.230; = 0.016) and RBDSQ-J scores (OR, 1.235; 95% CI, 1.007-1.516; = 0.043) as well as the SCOPA-AUT score (OR, 1.137; 95% CI, 1.006-1.285; = 0.040) were independent contributors to both sleep disturbances and EDS.
Autonomic symptoms were associated with patients with sleep disturbances or EDS, and depressive and RBD symptoms in addition to autonomic symptoms were associated with patients with both sleep disturbances and EDS.
睡眠障碍和日间过度嗜睡(EDS)是帕金森病(PD)患者常见的非运动症状。本研究旨在确定PD患者睡眠障碍的影响因素,包括失眠、不宁腿综合征、快速眼动睡眠行为障碍(RBD)、睡眠呼吸障碍、夜间运动不能和EDS。
我们进行了一项横断面研究,纳入了128例连续的日本PD患者。睡眠障碍和EDS分别定义为帕金森病睡眠量表-2(PDSS-2)总分≥15分和爱泼华嗜睡量表(ESS)评分>10分。根据是否存在睡眠障碍和EDS将患者分为四组。我们评估了疾病严重程度、运动症状、认知、嗅觉测试、帕金森病自主神经功能障碍结局量表(SCOPA-AUT)、贝克抑郁量表第二版(BDI-II)和RBD筛查问卷日本版(RBDSQ-J)。
128例患者中,64例既无EDS也无睡眠障碍,29例有睡眠障碍但无EDS,14例有EDS但无睡眠障碍,21例既有EDS又有睡眠障碍。有睡眠障碍的患者BDI-II评分高于无睡眠障碍的患者。与既无EDS也无睡眠障碍的患者相比,既有睡眠障碍又有EDS的患者中可能的RBD更常见。既无EDS也无睡眠障碍的患者SCOPA-AUT评分低于其他三组患者。以既无睡眠障碍也无EDS的组作为参照组进行多变量logistic回归分析,结果显示SCOPA-AUT评分是睡眠障碍(调整后的比值比[OR],1.192;95%可信区间[CI],1.065-1.333;P = 0.002)或EDS(OR,1.245;95%CI,1.087-1.424;P = 0.001)的独立影响因素,BDI-II(OR,1.121;95%CI,1.021-1.230;P = 0.016)、RBDSQ-J评分(OR,1.235;95%CI,1.007-1.516;P = 0.043)以及SCOPA-AUT评分(OR,1.137;95%CI,1.006-1.285;P = 0.040)是睡眠障碍和EDS的独立影响因素。
自主神经症状与有睡眠障碍或EDS的患者相关,除自主神经症状外,抑郁和RBD症状与既有睡眠障碍又有EDS的患者相关。